(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 November 2005 (03.11.2005)

PCT

(10) International Publication Number
WO 2005/102301 A2

(51) International Patent Classification[7]: A61K 31/19, 31/205, 31/202, 31/702, A61P 35/00, 31/00, 3/02, 19/02, 1/16, 1/12, 13/12, 11/00

(21) International Application Number: PCT/US2005/007951

(22) International Filing Date: 14 March 2005 (14.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/810,762 26 March 2004 (26.03.2004) US

(71) Applicant *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; Dept. 377/AP6A-1, 100 Abbott Park Road, Abbott Park, Il 60064 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **BAXTER, Jeffrey, H** [US/US]; 711 Caroway Blvd., Gahanna, OH 43230 (US). **MUKERJI, Pradip** [US/US]; 1069 Arcaro Drive, Gahanna, OH 43230 (US). **VOSS, Anne, C** [US/US]; 1526 Bridgeton Drive, Columbus, OH 43220 (US). **TISDALE, Michael, J** [GB/GB]; Aston University, Aston Triangle, Birmingham B4 7ET (GB).

(74) Agents: **WINTER, William, J.** et al.; 108140 DS1, 625 Cleveland Avenue, Columbus, OH 43215 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: HMB COMPOSITIONS AND USES THEREOF



(57) Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 w-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

WO 2005/102301 A2

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.